This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (479)  • Contact me when this article is cited  Related Content  • Related letter  • Related articles  • Similar articles in JAMA  Topic Collections  • Dermatology  • Connective Tissue Diseases  • Randomized Controlled Trial  • Rheumatoid Arthritis  • Immunologic Disorders  • Alert me on articles by topic

A Randomized Controlled Trial

Lee S. Simon, MD; Arthur L. Weaver, MD; David Y. Graham, MD; Alan J. Kivitz, MD; Peter E. Lipsky, MD; Richard C. Hubbard, MD; Peter C. Isakson, PhD; Kenneth M. Verburg, PhD; Shawn S. Yu, PhD; William W. Zhao, PhD; G. Steven Geis, PhD, MD

JAMA. 1999;282:1921-1928.

Context  In vitro studies have shown that celecoxib inhibits cyclooxygenase 2 (COX-2) but not COX-1, suggesting that this drug may have anti-inflammatory and analgesic activity without adverse upper gastrointestinal (GI) tract effects that result from COX-1 inhibition.

Objective  To test whether celecoxib has efficacy as an anti-inflammatory and analgesic with reduced GI tract mucosal damage compared with conventional nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis.

Design  Randomized, multicenter, placebo-controlled, double-blind trial lasting 12 weeks, with follow-up at weeks 2, 6, and 12, from September 1996 thorugh February 1998.

Setting  Seventy-nine clinical sites in the United States and Canada.

Patients  A total of 1149 patients aged 18 years or older with symptomatic rheumatoid arthritis who met inclusion criteria were randomized; 688 (60%) of these completed the study.

Interventions  Patients were randomized to receive celecoxib, 100 mg, 200 mg, or 400 mg twice per day (n = 240, 235, and 218, respectively); naproxen, 500 mg twice per day (n = 225); or placebo (n = 231).

Main Outcome Measures  Improvement in signs and symptoms of rheumatoid arthritis as assessed using standard measures of efficacy and GI tract safety as assessed by upper GI tract endoscopy before and after treatment, compared among treatment groups.

Results  All dosages of celecoxib and naproxen significantly improved the signs and symptoms of arthritis compared with placebo. Maximal anti-inflammatory and analgesic activity was evident within 2 weeks of initiating treatment and was sustained throughout the 12 weeks. The incidence of endoscopically determined gastroduodenal ulcers in placebo-treated patients was 4 (4%) of 99, and the incidences across all dosages of celecoxib were not significantly different (P>.40): 9 (6%) of 148 with 100 mg twice per day, 6 (4%) of 145 with 200 mg twice per day, and 8 (6%) of 130 with 400 mg twice per day. In contrast, the incidence with naproxen was 36 (26%) of 137, significantly greater than either placebo or celecoxib (P<.001). The overall incidences of GI tract adverse effects were 19% for placebo; 28%, 25%, and 26% for celecoxib 100 mg, 200 mg, and 400 mg twice per day, respectively; and 31% for naproxen.

Conclusion  In this study, all dosages of celecoxib were efficacious in the treatment of rheumatoid arthritis and did not affect COX-1 activity in the GI tract mucosa as evidenced by less frequent incidence of endoscopic ulcers compared with naproxen.

Author Affiliations: Department of Medicine, Division of Rheumatology and Metabolic Bone Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass (Dr Simon); the Arthritis Center of Nebraska, Lincoln (Dr Weaver); Department of Medicine, Veterans Affairs Medical Center/Baylor College of Medicine, Houston, Tex (Dr Graham); Altoona Center for Clinical Research, Altoona, Pa (Dr Kivitz); Rheumatic Diseases Division, University of Texas Southwestern Medical Center, Dallas (Dr Lipsky); and Departments of Clinical Research (Drs Hubbard, Verburg, Yu, Zhao, and Geis) and COX-2 Technology (Dr Isakson), Searle Research and Development, Skokie, Ill.

RELATED LETTER

Cyclooxygenase 2 Selective Agents and Upper Gastrointestinal Disease
Helen Fernandez, Gerson T. Lesser, Robert H. Palmer, and Lee S. Simon
JAMA. 2000;283(15):1961-1962.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Adverse Upper Gastrointestinal Effects of Rofecoxib Compared With NSAIDs
Michael J. Langman, Dennis M. Jensen, Douglas J. Watson, Sean E. Harper, Peng-Liang Zhao, Hui Quan, James A. Bolognese, and Thomas J. Simon
JAMA. 1999;282(20):1929-1933.
ABSTRACT | FULL TEXT  

COX-1–Sparing NSAIDs—Is the Enthusiasm Justified?
Walter L. Peterson and Byron Cryer
JAMA. 1999;282(20):1961-1963.
EXTRACT | FULL TEXT  

November 24, 1999
JAMA. 1999;282(20):1979-1980.
EXTRACT | FULL TEXT  

Living with arthritis
JAMA. 1999;282(20):1982.
PDF  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials
Scott et al.
Ann Rheum Dis 2007;66:1296-1304.
ABSTRACT | FULL TEXT  

Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice
Kiguchi et al.
Molecular Cancer Therapeutics 2007;6:1709-1717.
ABSTRACT | FULL TEXT  

Cardiovascular Effects of the Cyclooxygenase Inhibitors
White
Hypertension 2007;49:408-418.
FULL TEXT  

A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor {alpha} inhibitors
Yazici and Yazici
Ann Rheum Dis 2007;66:124-127.
ABSTRACT | FULL TEXT  

Shunting of prostanoid biosynthesis in microsomal prostaglandin E synthase-1 null embryo fibroblasts: regulatory effects on inducible nitric oxide synthase expression and nitrite synthesis
Kapoor et al.
FASEB J. 2006;20:2387-2389.
ABSTRACT | FULL TEXT  

Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials
Zhang et al.
JAMA 2006;296:1619-1632.
ABSTRACT | FULL TEXT  

Does Celecoxib Potentiate the Anticoagulant Effect of Warfarin? A Randomized, Double-Blind, Controlled Trial
Dentali et al.
The Annals of Pharmacotherapy 2006;40:1241-1247.
ABSTRACT | FULL TEXT  

The COX-2 Specific Inhibitor Valdecoxib Versus Tramadol in Acute Ankle Sprain: A Multicenter Randomized, Controlled Trial
Ekman et al.
Am J Sports Med 2006;34:945-955.
ABSTRACT | FULL TEXT  

Coxibs Versus Combination NSAID and PPI Therapy for Chronic Pain: An Exploration of the Risks, Benefits, and Costs
Hur et al.
The Annals of Pharmacotherapy 2006;40:1052-1063.
ABSTRACT | FULL TEXT  

Update on Cyclooxygenase-2 Inhibitors
Harris and Breyer
CJASN 2006;1:236-245.
ABSTRACT | FULL TEXT  

A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines
Price-Forbes et al.
Rheumatology (Oxford) 2005;44:921-924.
ABSTRACT | FULL TEXT  

Patient characteristics associated with outpatient prescriptions for nabumetone and oxaprozin versus celecoxib and rofecoxib
Brinker and Nourjah
Am J Health Syst Pharm 2005;62:739-743.
FULL TEXT  

Meta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure
Aw et al.
Arch Intern Med 2005;165:490-496.
ABSTRACT | FULL TEXT  

A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis
Lohmander et al.
Ann Rheum Dis 2005;64:449-456.
ABSTRACT | FULL TEXT  

The Janus Face of Cyclooxygenase-2 in Ischemic Stroke: Shifting Toward Downstream Targets
Iadecola and Gorelick
Stroke 2005;36:182-185.
FULL TEXT  

The analgesic efficacy of intramuscular parecoxib sodium in postoperative dental pain
MEHLISCH et al.
Journal of the American Dental Association 2004;135:1578-1590.
ABSTRACT | FULL TEXT  

Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Simmons et al.
Pharmacol. Rev. 2004;56:387-437.
ABSTRACT | FULL TEXT  

Reducing Clinically Significant Gastrointestinal Toxicity Associated with Nonsteroidal Antiinflammatory Drugs
Jacobsen and Phillips
The Annals of Pharmacotherapy 2004;38:1469-1481.
ABSTRACT | FULL TEXT  

Cyclooxygenase-2-regulated vascular endothelial growth factor release in gastric fibroblasts
Miura et al.
Am. J. Physiol. Gastrointest. Liver Physiol. 2004;287:G444-G451.
ABSTRACT | FULL TEXT  

Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis
Pincus et al.
Ann Rheum Dis 2004;63:931-939.
ABSTRACT | FULL TEXT  

Inhibition of Farnesyltransferase Prevents Collagen-Induced Arthritis by Down-Regulation of Inflammatory Gene Expression through Suppression of p21ras-Dependent NF-{kappa}B Activation
Na et al.
J. Immunol. 2004;173:1276-1283.
ABSTRACT | FULL TEXT  

For Discussion NSAIDs: gastroprotection or selective COX-2 inhibitor?
Dickman and Ellershaw
Palliat Med 2004;18:275-286.
ABSTRACT  

Acute Pain Following Musculoskeletal Injuries and Orthopaedic Surgery. Mechanisms and Management
Ekman and Koman
JBJS 2004;86:1316-1327.
FULL TEXT  

Concomitant Administration of Lumiracoxib and a Triphasic Oral Contraceptive Does Not Affect Contraceptive Activity or Pharmacokinetic Profile
Kalbag et al.
J Clin Pharmacol 2004;44:646-654.
ABSTRACT | FULL TEXT  

Cyclooxygenases, the Kidney, and Hypertension
Cheng and Harris
Hypertension 2004;43:525-530.
ABSTRACT | FULL TEXT  

Lumiracoxib: Pharmacokinetic and Pharmacodynamic Profile When Coadministered with Fluconazole in Healthy Subjects
Scott et al.
J Clin Pharmacol 2004;44:193-199.
ABSTRACT | FULL TEXT  

Risk of Uncomplicated Peptic Ulcer among Users of Aspirin and Nonaspirin Nonsteroidal Antiinflammatory Drugs
Garcia Rodriguez and Hernandez-Diaz
Am J Epidemiol 2004;159:23-31.
ABSTRACT | FULL TEXT  

Effect of COX-2-Specific Inhibition on Fracture-Healing in the Rat Femur
Brown et al.
JBJS 2004;86:116-123.
ABSTRACT | FULL TEXT  

Anti-inflammatory effect of two isoforms of COX in H. pylori-induced gastritis in mice: possible involvement of PGE2
Tanigawa et al.
Am. J. Physiol. Gastrointest. Liver Physiol. 2004;286:G148-G156.
ABSTRACT | FULL TEXT  

Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data
Layton et al.
Rheumatology (Oxford) 2003;42:1332-1341.
ABSTRACT | FULL TEXT  

Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial
Pavelka et al.
Rheumatology (Oxford) 2003;42:1207-1215.
ABSTRACT | FULL TEXT  

NSAIDs: the Emperor's new dogma?
Bjarnason et al.
Gut 2003;52:1376-1378.
ABSTRACT | FULL TEXT  

Adverse Drug Events Involving COX-2 Inhibitors
Verrico et al.
The Annals of Pharmacotherapy 2003;37:1203-1213.
ABSTRACT | FULL TEXT  

Dexibuprofen (S(+)-Isomer Ibuprofen) Reduces Gastric Damage and Improves Analgesic and Antiinflammatory Effects in Rodents
Bonabello et al.
Anesth. Analg. 2003;97:402-408.
ABSTRACT | FULL TEXT  

Pharmacoutilization and costs of osteoarthritis: changes induced by the introduction of a cyclooxygenase-2 inhibitor into clinical practice
Russo et al.
Rheumatology (Oxford) 2003;42:879-887.
ABSTRACT | FULL TEXT  

Analgesic effects of parecoxib following total abdominal hysterectomy{dagger}{ddagger}
Ng et al.
Br J Anaesth 2003;90:746-749.
ABSTRACT | FULL TEXT  

Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor
Dallob et al.
J Clin Pharmacol 2003;43:573-585.
ABSTRACT | FULL TEXT  

Cyclooxygenase-2 Inhibitors
Gajraj
Anesth. Analg. 2003;96:1720-1738.
FULL TEXT  

The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis
Spiegel et al.
ANN INTERN MED 2003;138:795-806.
ABSTRACT | FULL TEXT  

The COX-2 Selective Inhibitor, Valdecoxib, Does Not Impair Platelet Function in the Elderly: Results of a Randomized Controlled Trial
Leese et al.
J Clin Pharmacol 2003;43:504-513.
ABSTRACT | FULL TEXT  

Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors
Hawkey and Langman
Gut 2003;52:600-608.
ABSTRACT | FULL TEXT  

Characterization of Celecoxib and Valdecoxib Binding to Cyclooxygenase
Hood et al.
Mol. Pharmacol. 2003;63:870-877.
ABSTRACT | FULL TEXT  

Cyclooxygenase-2 Inhibitors in Gynecologic Practice
Connolly
Clin Med Res 2003;1:105-110.
ABSTRACT | FULL TEXT  

Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia
Hubbard et al.
Br J Anaesth 2003;90:166-172.
ABSTRACT | FULL TEXT  

Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis
Bae et al.
Rheumatology (Oxford) 2003;42:46-53.
ABSTRACT | FULL TEXT  

Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis
Chan et al.
NEJM 2002;347:2104-2110.
ABSTRACT | FULL TEXT  

Ankylosing spondylitis: introductory comments on its diagnosis and treatment
Khan
Ann Rheum Dis 2002;61:iii3-7.
FULL TEXT  

Ankylosing spondylitis: an overview
Sieper et al.
Ann Rheum Dis 2002;61:iii8-18.
ABSTRACT | FULL TEXT  

Conventional treatments for ankylosing spondylitis
Dougados et al.
Ann Rheum Dis 2002;61:iii40-50.
ABSTRACT | FULL TEXT  

Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials
Deeks et al.
BMJ 2002;325:619-619.
ABSTRACT | FULL TEXT  

Pharmacology of Celecoxib in Rat Brain after Kainate Administration
Ciceri et al.
J. Pharmacol. Exp. Ther. 2002;302:846-852.
ABSTRACT | FULL TEXT  

Paracetamol toxicity: epidemiology, prevention and costs to the health-care system
SHEEN et al.
QJM 2002;95:609-619.
ABSTRACT | FULL TEXT  

Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial
Labenz et al.
Gut 2002;51:329-335.
ABSTRACT | FULL TEXT  

Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users
Hawkey et al.
Gut 2002;51:344-350.
ABSTRACT | FULL TEXT  

Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen
Bensen et al.
Rheumatology (Oxford) 2002;41:1008-1016.
ABSTRACT | FULL TEXT  

Cyclooxygenase Inhibition for Postoperative Analgesia
McCrory and Lindahl
Anesth. Analg. 2002;95:169-176.
FULL TEXT  

Association Between Naproxen Use and Protection Against Acute Myocardial Infarction
Rahme et al.
Arch Intern Med 2002;162:1111-1115.
ABSTRACT | FULL TEXT  

The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery
DANIELS et al.
Journal of the American Dental Association 2002;133:611-621.
ABSTRACT | FULL TEXT  

Cyclooxygenase inhibition: between the devil and the deep blue sea
Hawkey
Gut 2002;50:iii25-30.
ABSTRACT | FULL TEXT  

Regulation of Prostaglandin Endoperoxide Synthase-2 and IL-6 Expression in Mouse Bone Marrow-Derived Mast Cells by Exogenous But Not Endogenous Prostanoids
Diaz et al.
J. Immunol. 2002;168:1397-1404.
ABSTRACT | FULL TEXT  

Clinical case study.
Haglund et al.
AM J HOSP PALLIAT CARE 2001;18:429-431.
 

A Cyclooxygenase-2 Inhibitor Impairs Ligament Healing in the Rat
Elder et al.
Am J Sports Med 2001;29:801-805.
ABSTRACT | FULL TEXT  

Quality Indicators for the Management of Osteoarthritis in Vulnerable Elders
MacLean
ANN INTERN MED 2001;135:711-721.
FULL TEXT  

How well is the clinical importance of study results reported? An assessment of randomized controlled trials
Chan et al.
CMAJ 2001;165:1197-1202.
ABSTRACT | FULL TEXT  

Cyclooxygenase 2{---}implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives
HALTER et al.
Gut 2001;49:443-453.
ABSTRACT | FULL TEXT  

Roles of Cyclooxygenase (COX)-1 and COX-2 in Prostanoid Production by Human Endothelial Cells: Selective Up-Regulation of Prostacyclin Synthesis by COX-2
Caughey et al.
J. Immunol. 2001;167:2831-2838.
ABSTRACT | FULL TEXT  

The Injectable Cyclooxygenase-2-Specific Inhibitor Parecoxib Sodium Has Analgesic Efficacy When Administered Preoperatively
Desjardins et al.
Anesth. Analg. 2001;93:721-727.
ABSTRACT | FULL TEXT  

The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald and Patrono
NEJM 2001;345:433-442.
FULL TEXT  

Ibuprofen to rofecoxib: What does it all mean and what do I do now?
Varga and Dickman
AM J HOSP PALLIAT CARE 2001;18:271-274.
ABSTRACT  

Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2
Riendeau et al.
J. Pharmacol. Exp. Ther. 2001;296:558-566.
ABSTRACT | FULL TEXT  

Pharmacokinetics of Celecoxib after Oral Administration in Dogs and Humans: Effect of Food and Site of Absorption
Paulson et al.
J. Pharmacol. Exp. Ther. 2001;297:638-645.
ABSTRACT | FULL TEXT  

Development and Use of a Gene Promoter-Based Screen to Identify Novel Inhibitors of Cyclooxygenase-2 Transcription
Subbaramaiah et al.
J Biomol Screen 2001;6:101-110.
ABSTRACT  

COX-2 inhibitors and the gastrointestinal tract
Bjarnason and Rainsford
Gut 2001;48:451-451.
FULL TEXT  

Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen
Shah et al.
Gut 2001;48:339-346.
ABSTRACT | FULL TEXT  

Guest Editorial: The Use of COX-2-Specific Inhibitors: Is It All Hype or Is It Evidence Based?
Ince
J. Gerontol. A Biol. Sci. Med. Sci. 2001;56:136M-137.
FULL TEXT  

Functional Status and Health-Related Quality of Life of Elderly Osteoarthritic Patients Treated With Celecoxib
Lisse et al.
J. Gerontol. A Biol. Sci. Med. Sci. 2001;56:167M-175.
ABSTRACT | FULL TEXT  

The Year in Review: Rheumatology
Rozenfeld et al.
Journal of Pharmacy Practice 2001;14:54-69.
ABSTRACT  

Safety of Celecoxib vs Other Nonsteroidal Anti-inflammatory Drugs
Kohler et al.
JAMA 2000;284:3123-3124.
FULL TEXT  

Role of cyclooxygenase-2 in modulating gastric acid secretion in the normal and inflamed rat stomach
Barnett et al.
Am. J. Physiol. Gastrointest. Liver Physiol. 2000;279:G1292-G1297.
ABSTRACT | FULL TEXT  

Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Bombardier et al.
NEJM 2000;343:1520-1528.
ABSTRACT | FULL TEXT  

Are {blacktriangledown}rofecoxib and {blacktriangledown}celecoxib safer NSAIDS?
DTB 2000;38:81-86.
ABSTRACT | FULL TEXT  

Recent advances: Rheumatology
Madhok et al.
BMJ 2000;321:882-885.
FULL TEXT  

Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial
Silverstein et al.
JAMA 2000;284:1247-1255.
ABSTRACT | FULL TEXT  

COX-2-Selective NSAIDs: New and Improved?
Lichtenstein and Wolfe
JAMA 2000;284:1297-1299.
FULL TEXT  

Selective Cox-2 inhibition in man--therapeutic breakthrough or cosmetic advance?
Wollheim
Rheumatology (Oxford) 2000;39:935-938.
FULL TEXT  

An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori
van Zanten et al.
CMAJ 2000;162:s3-23.
ABSTRACT | FULL TEXT  

Celecoxib was similar to naproxen for rheumatoid arthritis with fewer endoscopic ulcers
Henry and McGettigan
Evid. Based Med. 2000;5:75-75.
FULL TEXT  

Cyclooxygenase 2 Selective Agents and Upper Gastrointestinal Disease
Fernandez et al.
JAMA 2000;283:1961-1962.
FULL TEXT  

Effect of COX-2 Specific Inhibitors on GI Symptoms
JWatch Gastroenterology 2000;2000:4-4.
FULL TEXT  

A 55-Year-Old Woman With Rheumatoid Arthritis
Goldring
JAMA 2000;283:524-531.
FULL TEXT  

How Important Is the Benefit from COX-2 Inhibitors?
JWatch General 1999;1999:1-1.
FULL TEXT  

COX-1-Sparing NSAIDs--Is the Enthusiasm Justified?
Peterson and Cryer
JAMA 1999;282:1961-1963.
FULL TEXT  

Peroxisome Proliferator-activated Receptor gamma Ligands Suppress the Transcriptional Activation of Cyclooxygenase-2. EVIDENCE FOR INVOLVEMENT OF ACTIVATOR PROTEIN-1 AND CREB-BINDING PROTEIN/p300
Subbaramaiah et al.
J. Biol. Chem. 2001;276:12440-12448.
ABSTRACT | FULL TEXT  

Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice
Pratico et al.
Proc. Natl. Acad. Sci. USA 2001;98:3358-3363.
ABSTRACT | FULL TEXT  

Anti-inflammatories for cardiovascular disease
Masferrer and Needleman
Proc. Natl. Acad. Sci. USA 2000;97:12400-12401.
FULL TEXT